US 12,258,421 B2
Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
Alan Epstein, Los Angeles, CA (US); and Peisheng Hu, Los Angeles, CA (US)
Assigned to CANCER THERAPEUTICS LABORATORIES, INC., Los Angeles, CA (US)
Filed by Cancer Therapeutics Laboratories, Inc., Los Angeles, CA (US)
Filed on Jun. 14, 2022, as Appl. No. 17/839,953.
Application 17/839,953 is a division of application No. 16/496,177, granted, now 11,384,157, previously published as PCT/US2018/023123, filed on Mar. 19, 2018.
Claims priority of provisional application 62/473,554, filed on Mar. 20, 2017.
Prior Publication US 2023/0027730 A1, Jan. 26, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); A61K 47/68 (2017.01); A61K 51/10 (2006.01); A61P 31/18 (2006.01); C07K 16/00 (2006.01); C07K 16/44 (2006.01); C12N 5/077 (2010.01); C12N 15/10 (2006.01)
CPC C07K 16/44 (2013.01) [A61K 39/00 (2013.01); A61K 47/6801 (2017.08); A61K 51/10 (2013.01); C07K 16/005 (2013.01); C12N 15/1058 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A hybrid molecule comprising a binding portion of an antibody coupled to an immune stimulatory agent, wherein the binding portion comprises a heavy chain (VH) with three complementarity determining regions (H-CDRs) and a light chain (VL) with three CDRs (L-CDRs), wherein H-CDR1 comprises SEQ ID NO: 1, H-CDR2 comprises SEQ ID NO:2, H-CDR3 comprises a sequence selected from the group consisting of SEQ ID NOs:27-34, L-CDR1 comprises SEQ ID NO:4, L-CDR2 comprises SEQ ID NO:5, and L-CDR3 comprises SEQ ID NO:6.